M&A Deal Summary

Arbor Pharmaceuticals Acquires XenoPort

On May 23, 2016, Arbor Pharmaceuticals acquired life science company XenoPort for 467M USD

Acquisition Highlights
  • This is Arbor Pharmaceuticals’ 1st transaction in the Life Science sector.
  • This is Arbor Pharmaceuticals’ largest (disclosed) transaction.
  • This is Arbor Pharmaceuticals’ 1st transaction in the United States.
  • This is Arbor Pharmaceuticals’ 1st transaction in California.

M&A Deal Summary
Date 2016-05-23
Target XenoPort
Sector Life Science
Buyer(s) Arbor Pharmaceuticals
Deal Type Add-on Acquisition
Deal Value 467M USD
Advisor(s) Centerview Partners (Financial)
Weil Gotshal & Manges (Legal)

Target

XenoPort

Redwood City, California, United States
XenoPort, Inc. is a biopharmaceutical company focused on commercializing HORIZANT in the United States. XenoPort has entered into a clinical trial agreement with the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under which the NIAAA has initiated a clinical trial evaluating HORIZANT as a potential treatment for patients with alcohol use disorder.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Arbor Pharmaceuticals

Atlanta, Georgia, United States
Category Company
Sector Life Science
DESCRIPTION

Arbor Pharmaceuticals is a specialty pharmaceutical company with a diversified portfolio of branded products across multiple therapeutic areas for the cardiovascular, pediatric, and hospital markets as well as generic products through its Wilshire division. Arbor Pharmaceuticals is based in Atlanta, Georgia.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (California) 1 of 1
Country (United States) 1 of 1
Year (2016) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal